Autolus Therapeutics plc (NASDAQ:AUTL) Shares Purchased by Fmr LLC

FMR LLC boosted its stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 44.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,773,873 shares of the company's stock after buying an additional 5,478,706 shares during the quarter. FMR LLC owned approximately 6.68% of Autolus Therapeutics worth $64,519,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. ProShare Advisors LLC purchased a new position in Autolus Therapeutics during the 2nd quarter valued at about $43,000. Daiwa Securities Group Inc. increased its position in Autolus Therapeutics by 2,659.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company's stock valued at $55,000 after purchasing an additional 15,293 shares during the period. Herbst Group LLC purchased a new position in Autolus Therapeutics during the 3rd quarter valued at about $91,000. China Universal Asset Management Co. Ltd. increased its position in Autolus Therapeutics by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company's stock valued at $139,000 after purchasing an additional 14,959 shares during the period. Finally, Exchange Traded Concepts LLC increased its position in Autolus Therapeutics by 9.8% during the 3rd quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company's stock valued at $152,000 after purchasing an additional 3,740 shares during the period. Institutional investors own 72.83% of the company's stock.

Analysts Set New Price Targets

A number of research firms have commented on AUTL. The Goldman Sachs Group raised shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and raised their target price for the company from $7.00 to $7.60 in a research report on Monday, November 18th. Redburn Atlantic raised shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price objective on the stock in a research report on Friday, November 15th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research report on Thursday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $10.40.

Autolus Therapeutics Stock Up 0.7 %

Shares of Autolus Therapeutics stock traded up $0.02 on Friday, reaching $2.94. The stock had a trading volume of 1,254,396 shares, compared to its average volume of 2,156,088. Autolus Therapeutics plc has a 1 year low of $2.69 and a 1 year high of $7.45. The company has a 50 day moving average price of $3.68 and a 200 day moving average price of $3.88.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period last year, the firm posted ($0.26) EPS. On average, sell-side analysts predict that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.